google-site-verification: googlec7193c3de77668c9.html

Novel endocrine therapy improves disease-free survival over standard of care for patients with early-stage breast cancer

[
The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with the current standard-of-care endocrine therapy in patients with early-stage, hormone receptor (HR)-positive, HER2-negative breast cancer, according to the results of a Phase III IidERA trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9–12, 2025.


Source link

Advertisements
Views: 2

See also  Genomics-guided tool helps guide immunotherapy choices for advanced kidney cancers

Check Also

Among Black people in the U.S., country of birth associated with stroke risk

[ For Black individuals in the United States, being born in another country was associated …

AI flags heart failure risk five years early from routine ECG recordings

[ Perspective clinical scenario for using the DeepHHF score. Credit: npj Digital Medicine (2026). DOI: …

Brain's immune cells put the brakes on out-of-control circuits in mouse model of Alzheimer's disease

[ Researchers at Trinity College Dublin have discovered that microglia—the main immune cells of the …

Leave a Reply

Available for Amazon Prime
elfbar elfliq liquid. Where to buy elfbar vape.